- $23.97m
- $21.63m
- $0.07m
Brief: Vivos Inc. Strengthens Strategic Collaboration With Exubrion Therapeutics
Brief: Vivos Inc. Retains Top FDA Regulatory Expert Dr. John J. Smith, M.D., J.D., To Support Ide Submission For Radiogel®
Brief: Vivos Board Authorizes To Establish A Corporate Entity In India
Brief: Vivos Inc. Achieves Record Growth In IsoPet® Animal Cancer Treatments In Q1 2025
Brief: Vivos Reports Encouraging Human Clinical Trial Results and Announces Expansion Plans
Brief: Vivos Inc Obtains Feedback From The FDA On Clinical Testing Of Radiogel™
Brief: Vivos Inc. Files Early Feasibility Ide Application With FDA For Radiogel™
Brief: Vivos, Inc. Completes Common Stock Equity Financing To Fund Roll Out Of Isopet And Eliminate Toxic Debt
Brief: Vivos Inc Signs a Standstill Agreement with Debt Holders
Brief: Advanced Medical Isotope reports positive results from initial study at WSU